2019
Economic Evaluation of Extending Medicare Immunosuppressive Drug Coverage for Kidney Transplant Recipients in the Current Era
Kadatz M, Gill JS, Gill J, Formica RN, Klarenbach S. Economic Evaluation of Extending Medicare Immunosuppressive Drug Coverage for Kidney Transplant Recipients in the Current Era. Journal Of The American Society Of Nephrology 2019, 31: 218-228. PMID: 31704739, PMCID: PMC6934999, DOI: 10.1681/asn.2019070646.Peer-Reviewed Original ResearchConceptsKidney transplant recipientsQuality-adjusted life yearsTransplant recipientsTransplant survivalDrug coverageMedicare coverageTransplant failureImmunosuppressant drugsAdditional quality-adjusted life yearCohort of MedicareMultivariable survival analysisIncremental cost-utility ratioBetter patient outcomesCost-utility ratioImmunosuppressant medicationsTransplant functionImmunosuppressive drugsPatient outcomesMedicare payersSurvival analysisLife yearsIncremental costRecipientsSurvivalDrugs
2016
Integrase strand transferase inhibitors: the preferred antiretroviral regimen in HIV-positive renal transplantation
Azar MM, Malinis MF, Moss J, Formica RN, Villanueva MS. Integrase strand transferase inhibitors: the preferred antiretroviral regimen in HIV-positive renal transplantation. International Journal Of STD & AIDS 2016, 28: 447-458. PMID: 27193421, DOI: 10.1177/0956462416651528.Peer-Reviewed Original ResearchConceptsInhibitor-based regimensRenal transplantationHIV/AIDSAntiretroviral regimenAntiretroviral therapyGraft survivalHIV-positive renal transplant recipientsEnd-stage renal diseaseHIV-positive patientsRenal transplant recipientsChronic kidney diseaseThree-year survivalInhibitor-based therapyNon-nucleoside reverseDrug-drug interactionsTransferase inhibitorsImmunosuppressive medicationsKidney transplantationTransplant recipientsAllograft rejectionGraft failureRenal diseaseCalcineurin inhibitorsClinical outcomesImmunosuppressive drugs